<code id='1640FFDD28'></code><style id='1640FFDD28'></style>
      • <acronym id='1640FFDD28'></acronym>
      <center id='1640FFDD28'><center id='1640FFDD28'><tfoot id='1640FFDD28'></tfoot></center><abbr id='1640FFDD28'><dir id='1640FFDD28'><tfoot id='1640FFDD28'></tfoot><noframes id='1640FFDD28'>
      • <optgroup id='1640FFDD28'><strike id='1640FFDD28'><sup id='1640FFDD28'></sup></strike><code id='1640FFDD28'></code></optgroup>
        5. <b id='1640FFDD28'><label id='1640FFDD28'><select id='1640FFDD28'><dt id='1640FFDD28'><span id='1640FFDD28'></span></dt></select></label></b><u id='1640FFDD28'></u>
          <i id='1640FFDD28'><strike id='1640FFDD28'><tt id='1640FFDD28'><pre id='1640FFDD28'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / explore / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-10-02 07:40:18 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：explore   
                                        
                                      
                                      Page View：5422
                                  
                                    
          
                                   
          Darron Cummings/AP
          Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.
          The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.
          advertisement
          Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Senators: Long
                                
                            
          Next article：  
                                      
                                          Anesthesiologist group: stop taking Ozempic before surgery
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles